Trials / Completed
CompletedNCT01269021
An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)
Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 176 (actual)
- Sponsor
- Zhi-Hong Liu, M.D. · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
In order to treat proliferative IgA Nephropathy(IgAN), The investigators designed an open, prospective, randomized parallel study to access the efficacy and safety of MMF compared to corticosteroid . Patients who fulfill the inclusion criteria will be randomized in a 1:1 ratio to either the MMF group or corticosteroid group.
Detailed description
To access the efficacy and safety of MMF compared to corticosteroid in in treatment of proliferative IgA Nephropathy(IgAN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mycophenolate mofetil plus lower dose of Prednisone | MMF 1.0-1.5g/d\*6mons Prednisone 0.4-0.6 mg/kg/d |
| DRUG | Prednisone in full dose | 0.8-1mg/kg/d |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2013-10-01
- Completion
- 2014-04-01
- First posted
- 2011-01-04
- Last updated
- 2016-03-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01269021. Inclusion in this directory is not an endorsement.